eNLife Research Raises Rs 6 Crore Seed Funding Led by Piper Serica VC Fund
eNLife Research is developing an AI-powered platform capable of analysing up to 100 blood biomarkers to detect Alzheimer's disease up to 15 years before symptoms appear, and is collaborating with IISc, NIMHANS, TIFR Hyderabad, and the Centre for Brain Research to build India-specific biomarker datasets.
Bengaluru-based deeptech startup eNLife Research has raised ₹6 crore in a seed funding round led by Piper Serica VC Fund.
The company will use the newly raised capital to advance and validate its AI-powered blood biomarker platform, expand its research and development team in Bengaluru, and take its first diagnostic assay from the prototype stage to clinical-grade validation. It also plans to begin filing patents over the next 9 to 18 months covering biomarker binders, diagnostic assays, and its proprietary detection platform.
Founded in 2025 by Dr. Deepak Kumaran Nair, Lt. Col. Jojo Jacob, and Anish Mathew, eNLife Research is developing an AI-powered blood test designed to detect Alzheimer’s disease up to 15 years before clinical symptoms appear. Dr. Nair is also a professor at the Centre for Neuroscience at the Indian Institute of Science (IISc), and the startup is incubated at the Foundation for Science Innovation and Development (FSID) at IISc Bengaluru.
The platform currently analyses multiple Alzheimer’s-related biomarkers, including amyloid beta and abnormal tau proteins, while the company is developing next-generation assays capable of simultaneously evaluating up to 100 biomarkers for Alzheimer’s disease and other neurodegenerative disorders. Its AI engine is designed to identify complex biological patterns associated with disease progression at a much earlier stage.
eNLife Research is collaborating with researchers from the Indian Institute of Science (IISc), NIMHANS, TIFR Hyderabad, and the Centre for Brain Research (CBR), Bengaluru, to develop India-specific biomarker datasets tailored to the country’s genetic diversity and lifestyle-related risk factors.
The startup has already demonstrated proof of concept and is currently progressing toward clinical validation. It plans to commercialise its technology through partnerships with hospitals, diagnostic laboratories, and pharmaceutical companies, which can use the platform for both clinical diagnostics and drug development research.
Commenting on the mission, co-founder and CEO Dr. Deepak Kumaran Nair said,
“The biggest failure of Alzheimer’s care today isn’t the absence of treatments in trials; it’s that we find patients a decade too late to use them. We started eNLife to close both gaps at once: detect the disease at the molecular stage through a simple blood draw that is both accessible and affordable.”